Virtual ASCO took place from May 29 to May 31 where major oncology pharmaceutical companies presented their key abstracts. One such leader in oncology - GSK has advanced its innovative pipeline by focusing on science related to the immune system, the use of human genetics, and cutting-edge technologies that will advance the next wave of cancer therapies with the potential to transform outcomes for the patients.
In the ASCO meeting, GSK cell therapy and next-generation immuno-oncology investigational therapy included belantamab mafodotin, an antibody-drug conjugate for multiple myeloma, and GSK3359609, an inducible T-cell co-stimulator (ICOS) agonist for patients with head and neck cancer. As per Delveinsight analysis, as monotherapy and in a combination of pembrolizumab, ICOS GSK has blockbuster potential and is expected to generate a noteworthy revenue of more than USD 1 billion in the coming years after the successful launch in the market.
Another abstract- 4596 was for IMbrave150 trial of atezolizumab (atezo). A Phase III clinical trial for unresectable hepatocellular carcinoma (HCC) where complete responses were recorded in patients receiving atezo bev (atezolizumab + bevacizumab) vs sorafenib (sor) in IMbrave150. IMbrave 150 demonstrated a statistically significant and clinically meaningful improvement in both OS and PFS with atezo bev hcc vs sor in patients who have not received prior systemic therapy. The HCC result for atezo bev may shift the treatment paradigms for advanced HCC.
Abstract No. 5000 dealt with adjuvant treatment of high-risk muscle-invasive urothelial carcinoma with the PD-L1 inhibitor. ASCO's IMvigor010 trail results were presented by pharma giant Roche. Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC) were delivered.
IMvigor010, the first phase 3 adjuvant study of a checkpoint inhibitor in MIUC, did not meet its primary EP of DFS. More tx discontinuation due to AEs was seen vs mUC studies. Safety was generally consistent with previous studies.
Additionally, Abstract No. 5011 included the IMvigor130 study where tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) were considered.
IMvigor130 results reinforce the potential predictive nature of biomarkers associated with response/resistance to atezo and highlight potentially distinct biology driving benefit with atezo and atezo + PBC. These findings suggest a possible biomarker-directed approach to 1L mUC tx that warrants mechanistic interrogation and prospective validation.
Lastly, ASCO's Abstract - 8040 constituted Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell nonHodgkin lymphoma (NHL). The interim data suggest that elderly and/or comorbid pts with R/R aggressive large B-cell NHL, who are not eligible for high-dose chemotherapy and HSCT, can receive 2L liso cel with similar safety and efficacy to 3L+ patients as previously reported.
Latest Pharmaceutical Market Research Reports by DelveInsight
Technical due diligence firms | Stem cell market | Medical marijuana market | Oncolytic virus cancer therapy pipeline | Small lymphocytic lymphoma market |CART pipeline | Bone metastasis in solid tumors market | Kawasaki disease market | Myopia treatment devices market | urology ultrasounds devices market | Lice infestations market | Hepatic cirrhosis market | SGLT2 Inhibitors market | Pediatric growth hormone deficiency PGHD Market | Anti-neutrophil cytoplasmic antibody-associated vasculitis market | Varicella zoster HHV 3 infections market | Radiation induced esophagitis market
